A comprehensive dive into the contract research organization field offers a glimpse into how the virus has affected firms, and what the future might hold.
A leader from the contract research organization explains how home health personnel, decentralized trial technology and other services can help avoid study interruptions
A leader with the industry association discusses the surging interest in harnessing artificial intelligence to advance various treatments and therapies.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
A leader from the clinical development services firm recommends clinical trials change their tack to avoid costly clinical trial interruptions in the face of the pandemic.
The clinical trial company launched the trial around cytokine storm, an immunological reaction associated with severe virus cases, in 15 business days.
A leader with the patient recruitment specialist talks about the need for clinical trials to balance their important work with what’s important to participants.
The federal agency continues to monitor as the virus impacts the pharma and clinical trials industries, offering advice and taking action where necessary.
A representative of the research and development firm offers perspective on how the industry has shifted in recent years, thanks to a number of forces.
The healthcare institution and life-sciences technology platform are working together to use artificial intelligence to detect and understand the virus.
The company is putting artificial intelligence to work in the hopes of coming up with more precise, effective tests and therapies for a range of diseases.
The technology, developed by life-sciences software firm Deep Lens, integrates cancer genetic data into an advanced platform to connect patients with studies and treatments.
Produced by clinical trial software firm Florence Healthcare, the awards program seeks to recognize the contribution research professionals make to the industry.
The open-access resource, funded in part by the Bill and Melinda gates Foundation, is available to researchers, clinicians and others working on a cure.
A research team including MIT, Harvard and Stanford researchers has raised $20m in seed funding for their effort to map out immune cells with machine learning.
A representative of the life-sciences consulting firm outlines how the federal agency has reacted to the COVID-19 pandemic, and how it might advise the industry going forward.
The federal agency continues to offer advice for healthcare and pharma industry professionals, and to take action against companies acting out of bounds.
